research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
Search
for
Sort by
Research
300-330 / 1000+ results 
research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)
Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
COVID-19 vaccines can trigger autoimmune flares but are still beneficial for patients with autoimmune conditions.
research Bone infarcts in a woman with systemic lupus erythematosus and antiphospholipid antibody syndrome
A woman with lupus and antiphospholipid syndrome had bone damage, showing the need for careful treatment.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Lilly arthritis drug approved for alopecia
The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
research Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction
A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Purification and characterization of an immuno-stimulatory compound from the water extract of royoporus badius (Pers.) A.B. De.
A new compound from Royoporus badius activates immune cells and induces inflammatory responses.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research Managing Azathioprine-Induced Myelosuppression and Alopecia Totalis: Lessons from a SLE Patient
Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.
research Telitacicept for systemic lupus erythematosus with post‑surgical papillary thyroid carcinoma: A case report
Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
research Alopecia areata: from pathophysiology to therapeutic innovation
JAK inhibitors are effective treatments for alopecia areata.
research Two Birds that Exclude Each Other: The Renbök Phenomenon
Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
research Poster Presentations
Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Alopecia secondary to anti-tumor necrosis factor-alpha therapy
Anti-TNF therapy can cause hair loss and skin issues.
research Anti‐keratin Monoclonal Antibody against Basal Cell Epithelioma Keratin: BKN‐1
BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
research Reporte de caso: alopecia areata universal tratada exitosamente con baricitinib
Baricitinib successfully treated severe hair loss.
research Ottawa, Ontario, Canada, February 13–16, 2013
The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
Baricitinib shows promise for treating alopecia areata with mild side effects.